3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
11
NIH
5
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
108
Stomach Neoplasms
68
Pancreatic Neoplasms
33
Neoplasms
24
Lymphoma, Large B-Cell, Diffuse
22
Carcinoma, Non-Small-Cell Lung
21
Neoplasm Metastasis
18
Rectal Neoplasms
17
Colonic Neoplasms
17
Esophageal Neoplasms
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Adenocarcinoma
13
Carcinoma, Hepatocellular
12
Ovarian Neoplasms
10
Biliary Tract Neoplasms
9
Adenocarcinoma Of Esophagus
9
Esophageal Squamous Cell Carcinoma
8
Cholangiocarcinoma
8
Gastrointestinal Neoplasms
7
Lymphoma, Non-Hodgkin
6
Endometrial Neoplasms
6
Gallbladder Neoplasms
5
Advanced Solid Tumors
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Recurrence
4
Carcinoma, Pancreatic Ductal
4
Breast Neoplasms
4
Advanced Solid Tumor
4
Solid Tumors
3
Interventions
Gemcitabine
11
Cisplatin
10
pembrolizumab
7
Fluorouracil
3
Drug Therapy
3
spartalizumab
2
derazantinib
2
Leucovorin
2
trametinib
1
tislelizumab
1
silmitasertib
1
seribantumab
1
pertuzumab
1
olutasidenib
1
galactomannan
1
exatecan
1
durvalumab
1
becatecarin
1
Tegafur
1
Standard of Care
1
S 1 (combination)
1
Ritonavir
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Observation
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Microscopy, Confocal
1
Melphalan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Bile Duct Neoplasms
×
Oxaliplatin
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts